Genmab A/S (OTCMKTS:GNMSF) Short Interest Up 148.7% in August

Key Points

• Genmab A/S experienced a 148.7% increase in short interest in August, rising from 22,800 shares to 56,700 shares by August 31st.
• The company's stock remains stable at $284.18 with a market capitalization of $18.78 billion and a price-to-earnings ratio of 14.27.
• In its latest quarterly earnings, Genmab reported an EPS of $5.42, surpassing estimates and reflecting a revenue of $925 million, though falling short of analysts' expectations.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) saw a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 56,700 shares, a growth of 148.7% from the August 15th total of 22,800 shares. Currently, 0.1% of the company's shares are short sold. Based on an average daily trading volume, of 200 shares, the short-interest ratio is presently 283.5 days. Based on an average daily trading volume, of 200 shares, the short-interest ratio is presently 283.5 days. Currently, 0.1% of the company's shares are short sold.

Genmab A/S Stock Performance

Shares of Genmab A/S stock remained flat at $284.18 during trading hours on Friday. Genmab A/S has a 1-year low of $170.00 and a 1-year high of $284.18. The stock has a 50-day simple moving average of $232.82 and a two-hundred day simple moving average of $214.39. The stock has a market capitalization of $18.78 billion, a price-to-earnings ratio of 14.27 and a beta of 0.90.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $5.42 EPS for the quarter, beating the consensus estimate of $3.99 by $1.43. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million for the quarter, compared to analyst estimates of $949.06 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.